Publisher's Synopsis
The general interest in vaccines as a favored approach to the control of infectious disease has had a rebirth in recent years.;In part, the lack of interest prior to this rebirth has been the result of several factors, including very high development costs, corporate and even governmental liabilities when side effects or reversion to virulence injure or kill otherwise healthy individuals, and frustrating technical dead ends in developmental programs. This volume discusses promising new technologies which have become available during the past 15 years. These are enabling rapid advances in the understanding of molecular aspects of antigenicity and immune response and have opened entirely new avenues of pursuit in the development of safe and efficacious vaccines that were unthinkable only a few years ago.
